{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T02:47:51Z","timestamp":1788835671420,"version":"build-2803163510"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GlaxoSmithKline Biologicals SA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s40264-022-01242-8","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T18:02:55Z","timestamp":1668189775000},"page":"99-108","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Fully Liquid MenACWY-CRM Vaccine: Results from an Integrated Safety Analysis"],"prefix":"10.1007","volume":"46","clinical-trial-number":[{"clinical-trial-number":"nct03652610","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03433482","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1363-7815","authenticated-orcid":false,"given":"Puneet","family":"Vir Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7970-4980","authenticated-orcid":false,"given":"Paola","family":"Tiberi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9848-7360","authenticated-orcid":false,"given":"Gabriele Filippo","family":"Di Domenico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"Romolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9453-6302","authenticated-orcid":false,"given":"Thembile","family":"Mzolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4709-2590","authenticated-orcid":false,"given":"Marco","family":"Costantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tauseefullah","family":"Akhund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7475-7749","authenticated-orcid":false,"given":"Venere","family":"Basile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3457-426X","authenticated-orcid":false,"given":"Maria","family":"Lattanzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8505-9260","authenticated-orcid":false,"given":"Michele","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,11]]},"reference":[{"issue":"21","key":"1242_CR1","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1016\/j.vaccine.2019.04.020","volume":"37","author":"B Wang","year":"2019","unstructured":"Wang B, Santoreneos R, Giles L, Haji Ali Afzali H, Marshall H. Case fatality rates of invasive meningococcal disease by serogroup and age: a systematic review and meta-analysis. Vaccine. 2019;37(21):2768\u201382. https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.020.","journal-title":"Vaccine"},{"issue":"4","key":"1242_CR2","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40121-018-0213-2","volume":"7","author":"KJ Olbrich","year":"2018","unstructured":"Olbrich KJ, M\u00fcller D, Schumacher S, Beck E, Meszaros K, Koerber F. Systematic review of invasive meningococcal disease: sequelae and quality of life impact on patients and their caregivers. Infect Dis Ther. 2018;7(4):421\u201338. https:\/\/doi.org\/10.1007\/s40121-018-0213-2.","journal-title":"Infect Dis Ther"},{"key":"1242_CR3","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.jinf.2020.05.079","volume":"81","author":"S Parikh","year":"2020","unstructured":"Parikh S, Campbell H, Bettinger JA, Harrison LH, Marshall HS, Martinon-Torres F, et al. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. J Infect. 2020;81:483\u201398. https:\/\/doi.org\/10.1016\/j.jinf.2020.05.079.","journal-title":"J Infect"},{"key":"1242_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8101521","author":"M Pizza","year":"2020","unstructured":"Pizza M, Bekkat-Berkani R, Rappuoli R. Vaccines against meningococcal diseases. Microorganisms. 2020. https:\/\/doi.org\/10.3390\/microorganisms8101521.","journal-title":"Microorganisms."},{"key":"1242_CR5","doi-asserted-by":"publisher","DOI":"10.1080\/20477724.2021.1972663","author":"F Martin\u00f3n-Torres","year":"2021","unstructured":"Martin\u00f3n-Torres F, Taha MK, Knuf M, Abbing-Karahagopian V, Pellegrini M, Bekkat-Berkani R, et al. Evolving strategies for meningococcal vaccination in Europe: overview and key determinants for current and future considerations. Pathog Glob Health. 2021. https:\/\/doi.org\/10.1080\/20477724.2021.1972663.","journal-title":"Pathog Glob Health."},{"issue":"10","key":"1242_CR6","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1080\/14760584.2018.1521280","volume":"17","author":"P Keshavan","year":"2018","unstructured":"Keshavan P, Pellegrini M, Vadivelu-Pechai K, Nissen M. An update of clinical experience with the quadrivalent meningococcal ACWY-CRM conjugate vaccine. Expert Rev Vaccines. 2018;17(10):865\u201380. https:\/\/doi.org\/10.1080\/14760584.2018.1521280.","journal-title":"Expert Rev Vaccines"},{"key":"1242_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-021-00519-2","author":"Y Ruiz Garcia","year":"2021","unstructured":"Ruiz Garcia Y, Abitbol V, Pellegrini M, Bekkat-Berkani R, Soumahoro L. A decade of fighting invasive meningococcal disease: a narrative review of clinical and real-world experience with the MenACWY-CRM conjugate vaccine. Infect Dis Ther. 2021. https:\/\/doi.org\/10.1007\/s40121-021-00519-2.","journal-title":"Infect Dis Ther"},{"issue":"41","key":"1242_CR8","doi-asserted-by":"publisher","first-page":"5574","DOI":"10.1016\/j.vaccine.2009.07.036","volume":"27","author":"M Br\u00f6ker","year":"2009","unstructured":"Br\u00f6ker M, Dull PM, Rappuoli R, Costantino P. Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages. Vaccine. 2009;27(41):5574\u201380. https:\/\/doi.org\/10.1016\/j.vaccine.2009.07.036.","journal-title":"Vaccine"},{"issue":"45","key":"1242_CR9","doi-asserted-by":"publisher","first-page":"6409","DOI":"10.1016\/j.vaccine.2012.08.021","volume":"30","author":"F Berti","year":"2012","unstructured":"Berti F, Romano MR, Micoli F, Pinto V, Cappelletti E, Gavini M, et al. Relative stability of meningococcal serogroup A and X polysaccharides. Vaccine. 2012;30(45):6409\u201315. https:\/\/doi.org\/10.1016\/j.vaccine.2012.08.021.","journal-title":"Vaccine"},{"issue":"28","key":"1242_CR10","doi-asserted-by":"publisher","first-page":"3598","DOI":"10.1016\/j.vaccine.2017.03.066","volume":"35","author":"NJ Beresford","year":"2017","unstructured":"Beresford NJ, Martino A, Feavers IM, Corbel MJ, Bai X, Borrow R, et al. Quality, immunogenicity and stability of meningococcal serogroup ACWY-CRM197, DT and TT glycoconjugate vaccines. Vaccine. 2017;35(28):3598\u2013606. https:\/\/doi.org\/10.1016\/j.vaccine.2017.03.066.","journal-title":"Vaccine"},{"issue":"6","key":"1242_CR11","doi-asserted-by":"publisher","first-page":"161","DOI":"10.15585\/mmwr.mm6506a4","volume":"65","author":"JR Su","year":"2016","unstructured":"Su JR, Miller ER, Duffy J, Baer BM, Cano MV. Notes from the field: administration error involving a meningococcal conjugate vaccine\u2013United States, March 1, 2010\u2013September 22. MMWR Morb Mortal Wkly Rep. 2016;65(6):161\u20132. https:\/\/doi.org\/10.15585\/mmwr.mm6506a4.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"45","key":"1242_CR12","doi-asserted-by":"publisher","first-page":"6628","DOI":"10.1016\/j.vaccine.2021.09.068","volume":"39","author":"C Vandermeulen","year":"2021","unstructured":"Vandermeulen C, Leroux-Roels I, Vandeleur J, Staniscia T, Girard G, Ferguson M, et al. A new fully liquid presentation of MenACWY-CRM conjugate vaccine: results from a multicentre, randomised, controlled, observer-blind study. Vaccine. 2021;39(45):6628\u201336. https:\/\/doi.org\/10.1016\/j.vaccine.2021.09.068.","journal-title":"Vaccine"},{"issue":"1","key":"1242_CR13","doi-asserted-by":"publisher","first-page":"1981085","DOI":"10.1080\/21645515.2021.1981085","volume":"18","author":"J D\u00edez-Domingo","year":"2022","unstructured":"D\u00edez-Domingo J, Tinoco JC, Poder A, Dinleyici EC, Nell H, Salamanca de la Cueva I, et al. Immunological non-inferiority of a new fully liquid presentation of the MenACWY-CRM vaccine to the licensed vaccine: results from a randomized, controlled, observer-blind study in adolescents and young adults. Hum Vaccin Immunother. 2022;18(1):1981085. https:\/\/doi.org\/10.1080\/21645515.2021.1981085.","journal-title":"Hum Vaccin Immunother"},{"key":"1242_CR14","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2147\/idr.s12716","volume":"4","author":"M Br\u00f6ker","year":"2011","unstructured":"Br\u00f6ker M, Cooper B, Detora LM, Stoddard JJ. Critical appraisal of a quadrivalent CRM197 conjugate vaccine against meningococcal serogroups A, C W-135 and Y (Menveo) in the context of treatment and prevention of invasive disease. Infect Drug Resist. 2011;4:137\u201347. https:\/\/doi.org\/10.2147\/idr.s12716.","journal-title":"Infect Drug Resist."},{"key":"1242_CR15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ijid.2015.07.003","volume":"38","author":"S Lalwani","year":"2015","unstructured":"Lalwani S, Agarkhedkar S, Gogtay N, Palkar S, Agarkhedkar S, Thatte U, et al. Safety and immunogenicity of an investigational meningococcal ACWY conjugate vaccine (MenACWY-CRM) in healthy Indian subjects aged 2 to 75 years. Int J Infect Dis. 2015;38:36\u201342. https:\/\/doi.org\/10.1016\/j.ijid.2015.07.003.","journal-title":"Int J Infect Dis"},{"issue":"1","key":"1242_CR16","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1086\/599117","volume":"49","author":"LA Jackson","year":"2009","unstructured":"Jackson LA, Baxter R, Reisinger K, Karsten A, Shah J, Bedell L, et al. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. Clin Infect Dis. 2009;49(1):e1-10. https:\/\/doi.org\/10.1086\/599117.","journal-title":"Clin Infect Dis"},{"issue":"19","key":"1242_CR17","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1016\/j.vaccine.2020.03.017","volume":"38","author":"LJ Chang","year":"2020","unstructured":"Chang LJ, Hedrick J, Christensen S, Pan J, Jordanov E, Dhingra MS. A Phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United States. Vaccine. 2020;38(19):3560\u20139. https:\/\/doi.org\/10.1016\/j.vaccine.2020.03.017.","journal-title":"Vaccine"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-022-01242-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-022-01242-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-022-01242-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T16:11:10Z","timestamp":1673280670000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-022-01242-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,11]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["1242"],"URL":"https:\/\/doi.org\/10.1007\/s40264-022-01242-8","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,11]]},"assertion":[{"value":"19 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GlaxoSmithKline Biologicals SA funded this study\/research and was involved in all stages of study conduct, including analysis of the data. GlaxoSmithKline Biologicals SA also took in charge all costs associated with the development and publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"PVS, PT, GFDD, VR, TM, MC, VB, ML, and MP are employed by GSK. TA was employed by GSK when the analyses were conducted. PVS, TA, VB, ML, and MP hold shares in GSK. PVS, PT, GFDD, VR, TM, MC, TA, VB, ML, and MP declare no other financial and non-financial relationships and activities.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Anonymized individual participant data and study documents can be requested for further research from .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Studies #1 and #2 (NCT03652610 and NCT03433482) were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice and approved by the appropriate ethics committees.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Before enrolment in the studies, all individual participants aged at least 18 years provided written informed consent and parents\/legally acceptable representatives provided written informed consent for individual participants younger than 18 years.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"All authors contributed to the concept and design of the post hoc\u00a0analysis. PVS, PT, GFDD, VR, TM, MC, and VB contributed to data generation and collection. All authors contributed to the analysis of data. All authors contributed to the writing or review of the manuscript and approved the final version for submission.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"<i>Menveo<\/i> is a trademark owned by or licensed to GSK.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Trademark statement"}}]}}